ReviewJournal of immunology research2018
High-Risk Leukemia: Past, Present, and Future Role of NK Cells.
Review in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Optimisation of a primary human CAR-NK cell manufacturing pipeline.Clinical & translational immunology · 2024Article
- TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses.Cancer immunology, immunotherapy : CII · 2023Article
- Review
- Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.Clinical immunology (Orlando, Fla.) · 2021Review
- Human immunology and immunotherapy: main achievements and challenges.Cellular & molecular immunology · 2021Review
- Article
- Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.Frontiers in immunology · 2021Review
- Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear CellsFrontiers in immunology · 2021Article
- Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.Frontiers in immunology · 2020Article
- Deciphering Natural Killer Cell Homeostasis.Frontiers in immunology · 2020Review
- Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.Frontiers in immunology · 2020Review
- Review
- Killers 2.0: NK cell therapies at the forefront of cancer control.The Journal of clinical investigation · 2019Review
- Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument.Clinical hematology international · 2019Article
- Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells.International journal of molecular sciences · 2019Article
- Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.Frontiers in immunology · 2018Review
- Research Hotspots and Trends of NK Cell Immunotherapy for Acute Myeloid Leukemia: A Bibliometric Analysis From 2000 to 2023.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are a population of cytotoxic innate lymphocytes that evolved prior to their adaptive counterparts and constitute one of the first lines of defense against infected/mutated cells. Several studies have shown that in patients with acute leukemia given haploidentical hematopoietic stem cell transplantation, donor-derived NK cells play a key role in the eradication of cancer cells. The antileukemic effect is mostly related to the presence of "alloreactive" NK cells, that is, mature KIR+ NK cells that express inhibitory KIR mismatched with HLA class I (KIR-L) of the patient. A genotypic analysis detecting KIR B haplotype and the relative B content is an additional donor selection criterion. These data provided the rationale for implementing phase I/II clinical trials of adoptive infusion of either selected or ex vivo-activated NK cells, often from an HLA-mismatched donor. In this review, we provide a historical perspective on the role played by NK cells in patients with acute leukemia, focusing also on the various approaches to adoptive NK cell therapy and the unresolved issues therein. In addition, we outline new methods to enhance NK activity, including anti-KIR monoclonal antibody, bi-/trispecific antibodies linking NK cells to cytokines and/or target antigens, and CAR-engineered NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.